{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:35:45Z","timestamp":1794278145494,"version":"4.9.0"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"DOI":"10.1186\/s12906-025-04886-y","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T09:52:31Z","timestamp":1744451551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Are alterations needed in Silybum marianum (Silymarin) administration practices? A novel outlook and meta-analysis on randomized trials targeting liver injury"],"prefix":"10.1186","volume":"25","author":[{"given":"Kasra","family":"Shahsavari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shireen Shams","family":"Ardekani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza Shams","family":"Ardekani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid Mokaber","family":"Esfahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Kazemizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tannaz","family":"Jamialahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Iranshahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8392-9795","authenticated-orcid":false,"given":"Mahnaz","family":"Khanavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8260-6123","authenticated-orcid":false,"given":"Maede","family":"Hasanpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"issue":"3","key":"4886_CR1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/hep.21347","volume":"44","author":"R Williams","year":"2006","unstructured":"Williams R. Global challenges in liver disease. Hepatology. 2006;44(3):521\u20136.","journal-title":"Hepatology"},{"issue":"1","key":"4886_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/hep.23258","volume":"51","author":"RS O'shea","year":"2010","unstructured":"O\u2019shea RS, et al. Alcoholic liver disease. Hepatology. 2010;51(1):307\u201328.","journal-title":"Hepatology"},{"issue":"2","key":"4886_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1751-2980.2008.00331.x","volume":"9","author":"M De Zeng","year":"2008","unstructured":"De Zeng M, et al. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J Dig Dis. 2008;9(2):108\u201312.","journal-title":"J Dig Dis"},{"issue":"1","key":"4886_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"SK Asrani","year":"2019","unstructured":"Asrani SK, et al. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151\u201371.","journal-title":"J Hepatol"},{"key":"4886_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/tgh.2019.09.08","volume":"5","author":"S Mitra","year":"2020","unstructured":"Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl Gastroenterol Hepatol. 2020;5:16.","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"1","key":"4886_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2015.80","volume":"1","author":"EM Brunt","year":"2015","unstructured":"Brunt EM, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015;1(1):1\u201322.","journal-title":"Nat Rev Dis Primers"},{"issue":"16","key":"4886_CR7","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMra011775","volume":"346","author":"P Angulo","year":"2002","unstructured":"Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221\u201331.","journal-title":"N Engl J Med"},{"issue":"6","key":"4886_CR8","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1053\/gast.2002.33573","volume":"122","author":"JM Clark","year":"2002","unstructured":"Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002;122(6):1649\u201357.","journal-title":"Gastroenterology"},{"key":"4886_CR9","doi-asserted-by":"crossref","unstructured":"Strader DB, et al. Use of complementary and alternative medicine in patients with liver disease. Official J Am Coll Gastroenterol| ACG. 2002;97(9):2391\u20132397.","DOI":"10.1016\/S0002-9270(02)04350-2"},{"key":"4886_CR10","doi-asserted-by":"crossref","unstructured":"Rajaratnam M, et al. Herbal medicine for treatment and prevention of liver diseases. J Pre-Clin Clin Res. 2014;8(2):55\u201360.","DOI":"10.26444\/jpccr\/71468"},{"issue":"4","key":"4886_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.dld.2006.11.004","volume":"39","author":"F Stickel","year":"2007","unstructured":"Stickel F, Schuppan D. Herbal medicine in the treatment of liver diseases. Dig Liver Dis. 2007;39(4):293\u2013304.","journal-title":"Dig Liver Dis"},{"key":"4886_CR12","doi-asserted-by":"crossref","unstructured":"Corchete P. Silybum marianum (L.) Gaertn: the source of silymarin, Bioactive molecules and medicinal plants. 2008, Springer. p. 123\u201348.","DOI":"10.1007\/978-3-540-74603-4_6"},{"issue":"42","key":"4886_CR13","doi-asserted-by":"publisher","first-page":"11644","DOI":"10.1021\/acs.jafc.0c04791","volume":"68","author":"X Wang","year":"2020","unstructured":"Wang X, Zhang Z, Wu S-C. Health benefits of Silybum marianum: Phytochemistry, pharmacology, and applications. J Agric Food Chem. 2020;68(42):11644\u201364.","journal-title":"J Agric Food Chem"},{"key":"4886_CR14","unstructured":"Uysal \u0130.\u00a0A study on the biological activity of Silybum marianum (THISTLE). Int Res Sci Math. 2022:283."},{"key":"4886_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1385\/JMN:18:3:265","volume":"18","author":"S Kittur","year":"2002","unstructured":"Kittur S, et al. Neurotrophic and neuroprotective effects of milk thistle (Silybum marianum) on neurons in culture. J Mol Neurosci. 2002;18:265\u20139.","journal-title":"J Mol Neurosci"},{"key":"4886_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s11240-010-9692-x","volume":"101","author":"BH Abbasi","year":"2010","unstructured":"Abbasi BH, et al. Shoot regeneration and free-radical scavenging activity in Silybum marianum L. Plant Cell Tissue Organ Cult\u00a0(PCTOC). 2010;101:371\u20136.","journal-title":"Plant Cell Tissue Organ Cult\u00a0(PCTOC)"},{"key":"4886_CR17","first-page":"1","volume":"8","author":"F Bessam","year":"2014","unstructured":"Bessam F, Mehdadi Z. Evaluation of the antibacterial and antifongigal activity of different extract of flavono\u00efques Silybum marianum L. Adv Environ Biol. 2014;8:1\u20139.","journal-title":"Adv Environ Biol"},{"key":"4886_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.indcrop.2015.12.023","volume":"83","author":"L Lucini","year":"2016","unstructured":"Lucini L, et al. Phenolic profile and in vitro antioxidant power of different milk thistle [Silybum marianum (L.) Gaertn.] cultivars. Ind Crops Prod. 2016;83:11\u20136.","journal-title":"Ind Crops Prod"},{"issue":"2","key":"4886_CR19","first-page":"3061","volume":"19","author":"AF Al-Obaidi","year":"2019","unstructured":"Al-Obaidi AF, Rabie KM, Al-Mohammedi OHM. Evaluation of phytochemicals and biological activity of Silybum marianum L. Biochem Cell Arch. 2019;19(2):3061\u20136.","journal-title":"Biochem Cell Arch"},{"key":"4886_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.fitote.2017.04.008","volume":"119","author":"N-B Qin","year":"2017","unstructured":"Qin N-B, et al. New amides from seeds of Silybum marianum with potential antioxidant and antidiabetic activities. Fitoterapia. 2017;119:83\u20139.","journal-title":"Fitoterapia"},{"issue":"1","key":"4886_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/aab.12470","volume":"174","author":"DA Arampatzis","year":"2019","unstructured":"Arampatzis DA, Karkanis AC, Tsiropoulos NG. Silymarin content and antioxidant activity of seeds of wild Silybum marianum populations growing in Greece. Ann Appl Biol. 2019;174(1):61\u201373.","journal-title":"Ann Appl Biol"},{"issue":"8","key":"4886_CR22","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3390\/antiox8080304","volume":"8","author":"S Drouet","year":"2019","unstructured":"Drouet S, et al. A green ultrasound-assisted extraction optimization of the natural antioxidant and anti-aging flavonolignans from milk thistle Silybum marianum (L.) gaertn. fruits for cosmetic applications. Antioxidants. 2019;8(8):304.","journal-title":"Antioxidants"},{"key":"4886_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/B978-0-12-819547-5.00043-2","volume-title":"Cancer","author":"S Elyasi","year":"2021","unstructured":"Elyasi S. Silybum marianum, antioxidant activity, and cancer patients. In: Cancer. Elsevier; 2021. p. 483\u201393."},{"issue":"4","key":"4886_CR24","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3390\/molecules26040791","volume":"26","author":"M Shah","year":"2021","unstructured":"Shah M, et al. Chitosan elicitation impacts flavonolignan biosynthesis in Silybum marianum (L.) Gaertn cell suspension and enhances antioxidant and anti-inflammatory activities of cell extracts. Molecules. 2021;26(4):791.","journal-title":"Molecules"},{"issue":"2","key":"4886_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1572-0241.1998.00139.x","volume":"93","author":"K Flora","year":"1998","unstructured":"Flora K, et al. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol. 1998;93(2):139\u201343.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"4886_CR26","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/01.mcg.0000165668.79530.a0","volume":"39","author":"KR Ball","year":"2005","unstructured":"Ball KR, Kowdley KV. A review of Silybum marianum (milk thistle) as a treatment for alcoholic liver disease. J Clin Gastroenterol. 2005;39(6):520\u20138.","journal-title":"J Clin Gastroenterol"},{"key":"4886_CR27","doi-asserted-by":"crossref","unstructured":"Do\u011fru T, Eruygur N. Silybum marianum L. Gaertn, in Novel Drug Targets With Traditional Herbal Medicines: Scientific and Clinical Evidence. 2022, Springer. p. 543\u2013552.","DOI":"10.1007\/978-3-031-07753-1_35"},{"key":"4886_CR28","doi-asserted-by":"crossref","unstructured":"Ahmed S, et al. Effect of Silymarin as an adjunct therapy in combination with sofosbuvir and ribavirin in hepatitis c patients: a miniature clinical trial. Oxid Med Cell Longev. 2022;2022:1\u201314.","DOI":"10.1155\/2022\/9199190"},{"key":"4886_CR29","unstructured":"Wagner H, Diesel P, Seitz M. Chemistry and analysis of 'silymarin' from Silybum marianum. 1974."},{"key":"4886_CR30","doi-asserted-by":"crossref","unstructured":"Kaloga M.\u00a0Isosilychristin, ein neues Flayonolignan aus Silybum marianum L. Gaertn.\/Isosilychristin, a New Flavonolignan from Silybum marianum L. Gaertn. Zeitschrift f\u00fcr Naturforschung B. 1981. 36(2):262\u2013265.","DOI":"10.1515\/znb-1981-0225"},{"issue":"4","key":"4886_CR31","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1055\/s-2007-969717","volume":"50","author":"M Fiebig","year":"1984","unstructured":"Fiebig M, Wagner H. New antihepatotoxic effects of flavonolignans of a white flowering variety of Silybum. Planta Med. 1984;50(4):310\u20133.","journal-title":"Planta Med"},{"issue":"4","key":"4886_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1023\/A:1024782728074","volume":"37","author":"V Kurkin","year":"2003","unstructured":"Kurkin V. Saint-Mary thistle: a source of medicinals (a review). Pharm Chem J. 2003;37(4):189\u2013202.","journal-title":"Pharm Chem J"},{"issue":"01","key":"4886_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1055\/s-2006-962330","volume":"54","author":"AH Meri\u00e7li","year":"1988","unstructured":"Meri\u00e7li AH. Flavonolignans, kaempferol 3-sulphate and other flavonoids from Silybum marianum subsp. anatolicum. Planta Medica. 1988;54(01):44\u20135.","journal-title":"Planta Medica"},{"issue":"2","key":"4886_CR34","doi-asserted-by":"publisher","first-page":"101174","DOI":"10.1016\/j.aohep.2023.101174","volume":"29","author":"S Li","year":"2024","unstructured":"Li S, et al. Administration of Silymarin in NAFLD\/NASH: a systematic review and meta-analysis. Ann Hepatol. 2024;29(2):101174.","journal-title":"Ann Hepatol"},{"key":"4886_CR35","doi-asserted-by":"publisher","first-page":"111092","DOI":"10.1016\/j.nut.2020.111092","volume":"83","author":"G Kalopitas","year":"2021","unstructured":"Kalopitas G, et al. Impact of Silymarin in individuals with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Nutrition. 2021;83:111092.","journal-title":"Nutrition"},{"issue":"1","key":"4886_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3138\/canlivj-2023-0021","volume":"7","author":"A Malik","year":"2024","unstructured":"Malik A, Malik M, Qureshi S. Effects of silymarin use on liver enzymes and metabolic factors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. Canadian Liver J. 2024;7(1):40\u201353.","journal-title":"Canadian Liver J"},{"issue":"11","key":"4886_CR37","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.3390\/molecules24112155","volume":"24","author":"A Di Costanzo","year":"2019","unstructured":"Di Costanzo A, Angelico R. Formulation strategies for enhancing the bioavailability of silymarin: the state of the art. Molecules. 2019;24(11):2155.","journal-title":"Molecules"},{"key":"4886_CR38","doi-asserted-by":"crossref","unstructured":"Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372.","DOI":"10.1136\/bmj.n71"},{"key":"4886_CR39","doi-asserted-by":"crossref","unstructured":"Sterne JA, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366.","DOI":"10.1136\/bmj.l4898"},{"key":"4886_CR40","unstructured":"Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-Analysis Version 4. Biostat, Englewood, NJ, 2022."},{"issue":"6","key":"4886_CR41","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2018","unstructured":"Luo D, et al. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785\u2013805.","journal-title":"Stat Methods Med Res"},{"key":"4886_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, et al. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:1\u201313.","journal-title":"BMC Med Res Methodol"},{"issue":"10","key":"4886_CR43","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.21037\/jtd.2017.09.14","volume":"9","author":"A Hazra","year":"2017","unstructured":"Hazra A. Using the confidence interval confidently. J Thorac Dis. 2017;9(10):4125.","journal-title":"J Thorac Dis"},{"issue":"11","key":"4886_CR44","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"key":"4886_CR45","doi-asserted-by":"crossref","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088\u2013101.","DOI":"10.2307\/2533446"},{"issue":"7109","key":"4886_CR46","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"4","key":"4886_CR47","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3109\/00365528209182242","volume":"17","author":"HA Salmi","year":"1982","unstructured":"Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver: A double-blind controlled study. Scand J Gastroenterol. 1982;17(4):517\u201321.","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"4886_CR48","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0011-393X(05)80184-5","volume":"55","author":"G Palasciano","year":"1994","unstructured":"Palasciano G, et al. The effect of silymarin on plasma levels of malon-dialdehyde in patients receiving long-term treatment with psychotropic drugs. Curr Ther Res. 1994;55(5):537\u201345.","journal-title":"Curr Ther Res"},{"issue":"4","key":"4886_CR49","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S0168-8278(97)80255-3","volume":"26","author":"M Velussi","year":"1997","unstructured":"Velussi M, et al. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol. 1997;26(4):871\u20139.","journal-title":"J Hepatol"},{"issue":"4","key":"4886_CR50","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0168-8278(98)80285-7","volume":"28","author":"A Par\u00e9s","year":"1998","unstructured":"Par\u00e9s A, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: Results of a controlled, double-blind, randomized and multicenter trial. J Hepatol. 1998;28(4):615\u201321.","journal-title":"J Hepatol"},{"issue":"1","key":"4886_CR51","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5414\/CPP40002","volume":"40","author":"MI Lucena","year":"2002","unstructured":"Lucena MI, et al. Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study. Int J Clin Pharmacol Ther. 2002;40(1):2\u20138.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2 Suppl","key":"4886_CR52","first-page":"69","volume":"23","author":"M Torres","year":"2004","unstructured":"Torres M, et al. Does Silybum marianum play a role in the treatment of chronic hepatitis C? P R Health Sci J. 2004;23(2 Suppl):69\u201374.","journal-title":"P R Health Sci J"},{"issue":"SUPPL. 1","key":"4886_CR53","first-page":"13","volume":"4","author":"H Fallah Huseini","year":"2005","unstructured":"Fallah Huseini H, et al. The effect of Silymarin on glycemic control of type ii diabetes: a double blind randomized clinical trial. J Med Plants. 2005;4(SUPPL. 1):13\u20137.","journal-title":"J Med Plants"},{"key":"4886_CR54","unstructured":"HAJAGHA MA, ZIAEI A, Rafiei R. The efficacy of silymarin in decreasing transaminase activities in non-alcoholic fatty liver disease: a randomized controlled clinical trial. 2008."},{"issue":"26","key":"4886_CR55","first-page":"79","volume":"7","author":"M Ramezani","year":"2008","unstructured":"Ramezani M, et al. The effects of Silybum marianum (L.) Gaertn seed extract on glycemic control in type II diabetic patient\u2019s candidate for insulin therapy visiting endocrinology clinic in baqiyatallah hospital in the years of 2006. J Med Plants. 2008;7(26):79\u201384+94.","journal-title":"J Med Plants"},{"issue":"2","key":"4886_CR56","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.intimp.2013.04.016","volume":"16","author":"M Gharagozloo","year":"2013","unstructured":"Gharagozloo M, Karimi M, Amirghofran Z. Immunomodulatory effects of silymarin in patients with \u03b2-thalassemia major. Int Immunopharmacol. 2013;16(2):243\u20137.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"4886_CR57","first-page":"265","volume":"9","author":"SJ Hashemi","year":"2009","unstructured":"Hashemi SJ, Hajiani E, Sardabi EH. A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease. Hepat Mon. 2009;9(4):265\u201370.","journal-title":"Hepat Mon"},{"issue":"2","key":"4886_CR58","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/cncr.24723","volume":"116","author":"EJ Ladas","year":"2010","unstructured":"Ladas EJ, et al. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer. 2010;116(2):506\u201313.","journal-title":"Cancer"},{"issue":"3","key":"4886_CR59","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1001\/jama.2012.8265","volume":"308","author":"MW Fried","year":"2012","unstructured":"Fried MW, et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: A randomized controlled trial. JAMA. 2012;308(3):274\u201382.","journal-title":"JAMA"},{"issue":"8","key":"4886_CR60","doi-asserted-by":"publisher","first-page":"e6099","DOI":"10.5812\/hepatmon.6099","volume":"12","author":"AA Hajiaghamohammadi","year":"2012","unstructured":"Hajiaghamohammadi AA, et al. Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study. Hepat Mon. 2012;12(8):e6099.","journal-title":"Hepat Mon"},{"issue":"7","key":"4886_CR61","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/jvh.12050","volume":"20","author":"O Adeyemo","year":"2013","unstructured":"Adeyemo O, et al. Impact of oral silymarin on virus- and non-virus-specific T-cell responses in chronic hepatitis C infection. J Viral Hepatitis. 2013;20(7):453\u201362.","journal-title":"J Viral Hepatitis"},{"issue":"1","key":"4886_CR62","doi-asserted-by":"publisher","first-page":"e2013065","DOI":"10.4084\/mjhid.2013.065","volume":"5","author":"AA Hagag","year":"2013","unstructured":"Hagag AA, et al. Therapeutic value of combined therapy with deferasirox and silymarin on iron overload in children with Beta thalassemia. Mediterr J Hematol Infect Dis. 2013;5(1):e2013065.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"3","key":"4886_CR63","first-page":"181","volume":"18","author":"M Masoodi","year":"2013","unstructured":"Masoodi M, et al. Effects of silymarin on reducing liver aminotransferases in patients with nonalcoholic fatty liver diseases. Govaresh. 2013;18(3):181\u20135.","journal-title":"Govaresh"},{"issue":"3","key":"4886_CR64","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/ejh.12061","volume":"90","author":"B Moayedi","year":"2013","unstructured":"Moayedi B, et al. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in beta-thalassemia major patients receiving desferrioxamine. Eur J Haematol. 2013;90(3):202\u20139.","journal-title":"Eur J Haematol"},{"issue":"98","key":"4886_CR65","first-page":"164","volume":"23","author":"T Taghvaei","year":"2013","unstructured":"Taghvaei T, et al. Efficacy of silymarin on treatment of nonalcoholic steatohepatitis. J Mazandaran Univ Med Sci. 2013;23(98):164\u201371.","journal-title":"J Mazandaran Univ Med Sci"},{"issue":"4","key":"4886_CR66","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.5455\/medscience.2014.03.8173","volume":"3","author":"SF El Menshawe","year":"2014","unstructured":"El Menshawe SF, et al. Study of hepatoprotective effect of silymarin and ursodeoxycholic acid in chronic Hepatitis C Patients. Med Sci. 2014;3(4):1655\u201374.","journal-title":"Med Sci"},{"issue":"1","key":"4886_CR67","first-page":"9","volume":"5","author":"H Solhi","year":"2014","unstructured":"Solhi H, et al. Silymarin in treatment of non-alcoholic steatohepatitis: A randomized clinical trial. Caspian J Intern Med. 2014;5(1):9\u201312.","journal-title":"Caspian J Intern Med"},{"issue":"7","key":"4886_CR68","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/tri.12324","volume":"27","author":"M Rendina","year":"2014","unstructured":"Rendina M, et al. Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: a randomized clinical trial. Transpl Int. 2014;27(7):696\u2013704.","journal-title":"Transpl Int"},{"key":"4886_CR69","unstructured":"Okonkwo Uchenna, C., A. Anthony, and E. Emmanuel. Effects of silymarin on treatment na\u00efve patients with chronic hepatitis b infection-a randomized controlled trial. J Infect Dis Ther. 2014;2(168):2332\u20130877.1000168."},{"issue":"6","key":"4886_CR70","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.eujim.2015.10.012","volume":"7","author":"F Mohaghegh","year":"2015","unstructured":"Mohaghegh F, Solhi H, Kazemifar AM. Silymarin (Milk Thistle) can revoke liver enzyme changes during chemotherapy of breast cancer with Taxanes. European J Integr Med. 2015;7(6):650\u20132.","journal-title":"European J Integr Med"},{"issue":"1","key":"4886_CR71","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12906-015-0861-7","volume":"15","author":"C Luangchosiri","year":"2015","unstructured":"Luangchosiri C, et al. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury. BMC Complement Altern Med. 2015;15(1):334.","journal-title":"BMC Complement Altern Med"},{"issue":"12","key":"4886_CR72","first-page":"46","volume":"26","author":"IA Memon","year":"2015","unstructured":"Memon IA, Akbar M, Bhurgri AN. Effect of silymarin therapy on liver aminotransferase in non-alcoholic fatty liver disease. Med Forum Mon. 2015;26(12):46\u20139.","journal-title":"Med Forum Mon"},{"issue":"3","key":"4886_CR73","doi-asserted-by":"publisher","first-page":"249","DOI":"10.21037\/hbsn.2016.02.06","volume":"5","author":"ZA Salama","year":"2016","unstructured":"Salama ZA, et al. Losartan may inhibit the progression of liver fibrosis in chronic HCV patients. Hepatobiliary Surg Nutr. 2016;5(3):249\u201355.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"1","key":"4886_CR74","doi-asserted-by":"publisher","first-page":"e2016043","DOI":"10.4084\/mjhid.2016.043","volume":"8","author":"AA Hagag","year":"2016","unstructured":"Hagag AA, et al. Protective role of silymarin on hepatic and renal toxicity induced by mtx based chemotherapy in children with acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis. 2016;8(1):e2016043.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"2","key":"4886_CR75","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/jgh.13070","volume":"31","author":"S Zhang","year":"2016","unstructured":"Zhang S, et al. Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury: a randomized controlled trial. J Gastroenterol Hepatol (Australia). 2016;31(2):409\u201316.","journal-title":"J Gastroenterol Hepatol (Australia)"},{"issue":"3","key":"4886_CR76","doi-asserted-by":"publisher","first-page":"265","DOI":"10.4046\/trd.2017.80.3.265","volume":"80","author":"E Heo","year":"2017","unstructured":"Heo E, et al. Effect of Prophylactic Use of Silymarin on Anti-tuberculosis Drugs Induced Hepatotoxicity. Tuberc Respir Dis (Seoul). 2017;80(3):265\u20139.","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"4886_CR77","doi-asserted-by":"crossref","unstructured":"Kheong CW, Mustapha NRN, Mahadeva S. A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2017;15(12):1940\u20131949. e8.","DOI":"10.1016\/j.cgh.2017.04.016"},{"issue":"3","key":"4886_CR78","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/S1499-3872(16)60142-X","volume":"16","author":"M Asgarshirazi","year":"2017","unstructured":"Asgarshirazi M, Shariat M, Sheikh M. Comparison of efficacy of folic acid and silymarin in the management of antiepileptic drug induced liver injury: a randomized clinical trial. Hepatobiliary Pancreat Dis Int. 2017;16(3):296\u2013302.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"8","key":"4886_CR79","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.19082\/5098","volume":"9","author":"FK Baghbahadorani","year":"2017","unstructured":"Baghbahadorani FK, Miraj S. The Impact of silymarin on improvement of hepatic abnormalities in patients with severe preeclampsia: a randomized clinical trial. Electron Phys. 2017;9(8):5098\u2013106.","journal-title":"Electron Phys"},{"issue":"1","key":"4886_CR80","first-page":"16","volume":"6","author":"F Famouri","year":"2017","unstructured":"Famouri F, et al. The effect of silymarin on non-alcoholic fatty liver disease of children. J HerbMed Pharmacol. 2017;6(1):16\u201320.","journal-title":"J HerbMed Pharmacol"},{"issue":"11","key":"4886_CR81","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1089\/jir.2017.0051","volume":"37","author":"WF Fathalah","year":"2017","unstructured":"Fathalah WF, et al. High dose of silymarin in patients with decompensated liver disease: a randomized controlled trial. J Interferon Cytokine Res. 2017;37(11):480\u20137.","journal-title":"J Interferon Cytokine Res"},{"issue":"5","key":"4886_CR82","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/MEG.0000000000001369","volume":"31","author":"A Anushiravani","year":"2019","unstructured":"Anushiravani A, et al. Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial. Eur J Gastroenterol Hepatol. 2019;31(5):613\u20137.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"4886_CR83","first-page":"138","volume":"12","author":"M Marjani","year":"2019","unstructured":"Marjani M, et al. Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial. Gastroenterol Hepatol Bed Bench. 2019;12(2):138\u201342.","journal-title":"Gastroenterol Hepatol Bed Bench"},{"issue":"2","key":"4886_CR84","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40200-020-00576-3","volume":"19","author":"C Colletta","year":"2020","unstructured":"Colletta C, Colletta A, Placentino G. Lifestyle and silymarin: a fight against liver damage in NAFLD associated - prediabetic disease. J Diabetes Metab Disord. 2020;19(2):883\u201394.","journal-title":"J Diabetes Metab Disord"},{"issue":"2","key":"4886_CR85","doi-asserted-by":"publisher","first-page":"299","DOI":"10.31925\/farmacia.2020.2.15","volume":"68","author":"O Fr\u0103\u021bil\u0103","year":"2020","unstructured":"Fr\u0103\u021bil\u0103 O, et al. Comparative hepatoprotective efficacy of silymarin-phyllanthus-choline combination versus silymarin alone in liver diseases with different destruction and inflammation stages. Farmacia. 2020;68(2):299\u2013306.","journal-title":"Farmacia"},{"issue":"2","key":"4886_CR86","doi-asserted-by":"publisher","first-page":"e13236","DOI":"10.1111\/dth.13236","volume":"33","author":"M Mirnezami","year":"2020","unstructured":"Mirnezami M, et al. The effect of silymarin on liver enzymes in patients taking isotretinoin: A randomized clinical trial. Dermatol Ther. 2020;33(2):e13236.","journal-title":"Dermatol Ther"},{"issue":"4","key":"4886_CR87","first-page":"255","volume":"11","author":"A Eghbali","year":"2021","unstructured":"Eghbali A, et al. A randomized, controlled study evaluating the effects of silymarin addition to deferasirox on the liver function of children with transfusion-dependent thalassemia. Iran J Pediatr Hematol Oncol. 2021;11(4):255\u201362.","journal-title":"Iran J Pediatr Hematol Oncol"},{"key":"4886_CR88","doi-asserted-by":"crossref","unstructured":"Abbasirad F, et al. Significant immunomodulatory and hepatoprotective impacts of Silymarin in MS patients: a double-blind placebo-controlled clinical trial. Int Immunopharmacol. 2021;97.","DOI":"10.1016\/j.intimp.2021.107715"},{"key":"4886_CR89","doi-asserted-by":"crossref","unstructured":"Ghiasian M, et al. Antioxidative effects of silymarin on the reduction of liver complications of fingolimod in patients with relapsing\u2013remitting multiple sclerosis: a clinical trial study. J Biochem Mol Toxicol. 2021;35(8):e22800.","DOI":"10.1002\/jbt.22800"},{"issue":"2","key":"4886_CR90","doi-asserted-by":"publisher","first-page":"149","DOI":"10.5114\/ceh.2021.107067","volume":"7","author":"E Mirzaei","year":"2021","unstructured":"Mirzaei E, et al. The effect of silymarin on liver enzymes and antioxidant status in trauma patients in the intensive care unit: a randomized double blinded placebo-controlled clinical trial. Clin Exp Hepatol. 2021;7(2):149\u201355.","journal-title":"Clin Exp Hepatol"},{"issue":"3","key":"4886_CR91","first-page":"173","volume":"4","author":"S Shabani","year":"2021","unstructured":"Shabani S, et al. The effects of silymarin and N-acetylcysteine on liver and kidney dysfunction in subjects with severe pre-eclampsia. J Iran Med Counc. 2021;4(3):173\u201382.","journal-title":"J Iran Med Counc"},{"issue":"5","key":"4886_CR92","first-page":"455","volume":"44","author":"M Hamidi","year":"2021","unstructured":"Hamidi M. Phytotherapy with silymarin: a clinical trial on infants with jaundice. Erciyes Med J. 2021;44(5):455\u20139.","journal-title":"Erciyes Med J"},{"key":"4886_CR93","doi-asserted-by":"publisher","first-page":"100190","DOI":"10.1016\/j.metop.2022.100190","volume":"14","author":"SH Mirhashemi","year":"2022","unstructured":"Mirhashemi SH, et al. Effect of 8 Weeks milk thistle powder (silymarin extract) supplementation on fatty liver disease in patients candidates for bariatric surgery. Metabol Open. 2022;14:100190.","journal-title":"Metabol Open"},{"issue":"4","key":"4886_CR94","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1177\/10781552211006182","volume":"28","author":"GSA Moezian","year":"2022","unstructured":"Moezian GSA, et al. Oral silymarin formulation efficacy in management of AC-T protocol induced hepatotoxicity in breast cancer patients: A randomized, triple blind, placebo-controlled clinical trial. J Oncol Pharm Pract. 2022;28(4):827\u201335.","journal-title":"J Oncol Pharm Pract"},{"key":"4886_CR95","doi-asserted-by":"publisher","first-page":"1089938","DOI":"10.3389\/fendo.2022.1089938","volume":"13","author":"V Nehmi-Filho","year":"2022","unstructured":"Nehmi-Filho V, et al. Novel nutraceutical supplements with yeast beta-glucan, prebiotics, minerals, and Silybum marianum (silymarin) ameliorate obesity-related metabolic and clinical parameters: a double-blind randomized trial. Front Endocrinol (Lausanne). 2022;13:1089938.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"4886_CR96","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4103\/jrms.jrms_683_21","volume":"27","author":"H Atarodi","year":"2022","unstructured":"Atarodi H, et al. Effect of silymarin on liver size and nonalcoholic fatty liver disease in morbidly obese patients: A randomized double-blind clinical trial. Journal of Research in Medical Sciences. 2022;27(1):76.","journal-title":"Journal of Research in Medical Sciences"},{"issue":"10","key":"4886_CR97","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1002\/ptr.7537","volume":"36","author":"H Aryan","year":"2022","unstructured":"Aryan H, et al. Evaluation of the efficacy of oral nano-silymarin formulation in hospitalized patients with COVID-19: a double-blind placebo-controlled clinical trial. Phytother Res. 2022;36(10):3924\u201331.","journal-title":"Phytother Res"},{"issue":"4","key":"4886_CR98","first-page":"95","volume":"28","author":"A Alimoradian","year":"2023","unstructured":"Alimoradian A, et al. Effect of silymarin on hepatic complications caused by methotrexate and its analgesic effects in patients with rheumatoid arthritis. Sci J Kurdistan Univ Med Sci. 2023;28(4):95\u2013109.","journal-title":"Sci J Kurdistan Univ Med Sci"},{"issue":"1","key":"4886_CR99","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/13813455.2020.1797104","volume":"129","author":"K Ghalandari","year":"2023","unstructured":"Ghalandari K, et al. Effect of aerobic training with silymarin consumption on glycemic indices and liver enzymes in men with type 2 diabetes. Arch Physiol Biochem. 2023;129(1):76\u201381.","journal-title":"Arch Physiol Biochem"},{"key":"4886_CR100","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4103\/ijpvm.ijpvm_81_22","volume":"14","author":"A Talebi","year":"2023","unstructured":"Talebi A, et al. The effectiveness of silymarin in the prevention of anti-tuberculosis drug-induced hepatotoxicity: a randomized controlled clinical trial. Int J Prev Med. 2023;14:48.","journal-title":"Int J Prev Med"},{"key":"4886_CR101","unstructured":"Lala V, Zubair M, Minter D. Liver function tests. StatPearls, 2023."},{"key":"4886_CR102","unstructured":"Friedman S, Martin P, Munoz J. Laboratory evaluation of the patient with liver disease. Hepatology, a textbook of liver disease. Philedelphia; Saunders publication. 2003;1:661\u2013709."},{"issue":"3","key":"4886_CR103","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/0168-8278(91)90829-Z","volume":"12","author":"G Nassuato","year":"1991","unstructured":"Nassuato G, et al. Effect of Silibinin on biliary lipid composition experimental and clinical study. J Hepatol. 1991;12(3):290\u20135.","journal-title":"J Hepatol"},{"key":"4886_CR104","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00210-020-02040-8","volume":"394","author":"MM Ommati","year":"2021","unstructured":"Ommati MM, et al. Silymarin mitigates bile duct obstruction-induced cholemic nephropathy. Naunyn Schmiedebergs Arch Pharmacol. 2021;394:1301\u201314.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"5","key":"4886_CR105","doi-asserted-by":"publisher","first-page":"8713","DOI":"10.3390\/ijms15058713","volume":"15","author":"F Nassir","year":"2014","unstructured":"Nassir F, Ibdah JA. Role of mitochondria in nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15(5):8713\u201342.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"4886_CR106","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.clinbiochem.2012.03.024","volume":"45","author":"I Grattagliano","year":"2012","unstructured":"Grattagliano I, et al. Role of mitochondria in nonalcoholic fatty liver disease-from origin to propagation. Clin Biochem. 2012;45(9):610\u20138.","journal-title":"Clin Biochem"},{"key":"4886_CR107","doi-asserted-by":"crossref","unstructured":"Pessayre D, Mansouri A, Fromenty B. V. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2002;282(2):G193-G199.","DOI":"10.1152\/ajpgi.00426.2001"},{"issue":"1","key":"4886_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mito.2005.10.004","volume":"6","author":"K Begriche","year":"2006","unstructured":"Begriche K, et al. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion. 2006;6(1):1\u201328.","journal-title":"Mitochondrion"},{"issue":"6","key":"4886_CR109","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","volume":"69","author":"Z Younossi","year":"2019","unstructured":"Younossi Z, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672\u201382.","journal-title":"Hepatology"},{"key":"4886_CR110","unstructured":"Mulrow C, et al. Milk thistle: effects on liver disease and cirrhosis and clinical adverse effects: summary, AHRQ evidence report summaries. Agency for Healthcare Research and Quality (US). 2000."},{"key":"4886_CR111","unstructured":"Sonnenbichler J. Biochemical effects of the flavonolignane silibinin on mRNA, protein, and RNA synthesis in rat livers. Plant Flavonoids Biol Med. 1986:319\u2013331."},{"issue":"3","key":"4886_CR112","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/0006-2952(86)90233-9","volume":"35","author":"J Sonnenbichler","year":"1986","unstructured":"Sonnenbichler J, et al. Stimulatory effect of Silibinin on the DNA synthesis in partially hepatectomized rat livers: non-response in hepatoma and other malign cell lines. Biochem Pharmacol. 1986;35(3):538\u201341.","journal-title":"Biochem Pharmacol"},{"key":"4886_CR113","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/978-3-642-72631-6_34","volume-title":"Assessment and management of hepatobiliary disease","author":"J Sonnenbichler","year":"1987","unstructured":"Sonnenbichler J, Zetl I. Stimulating influence of a flavonolignane derivative on proliferation, RNA synthesis and protein synthesis in liver cells. In: Assessment and management of hepatobiliary disease. Springer; 1987. p. 265\u201372."},{"issue":"3","key":"4886_CR114","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1248\/bpb.17.443","volume":"17","author":"D Kim","year":"1994","unstructured":"Kim D, et al. Silymarin and its components are inhibitors of \u03b2-glucuronidase. Biol Pharm Bull. 1994;17(3):443\u20135.","journal-title":"Biol Pharm Bull"},{"key":"4886_CR115","doi-asserted-by":"crossref","unstructured":"Jaffar HM, et al. Silymarin: unveiling its pharmacological spectrum and therapeutic potential in liver diseases\u2014a comprehensive narrative review. Food Sci Nutr. 2024.","DOI":"10.1002\/fsn3.4010"},{"issue":"10","key":"4886_CR116","doi-asserted-by":"publisher","first-page":"792","DOI":"10.2174\/1568009623666230418121130","volume":"23","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. The role of oxidative stress in the development and therapeutic intervention of hepatocellular carcinoma. Curr Cancer Drug Targets. 2023;23(10):792\u2013804.","journal-title":"Curr Cancer Drug Targets"},{"issue":"6","key":"4886_CR117","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.etp.2010.04.009","volume":"63","author":"S Aghazadeh","year":"2011","unstructured":"Aghazadeh S, et al. Anti-apoptotic and anti-inflammatory effects of Silybum marianum in treatment of experimental steatohepatitis. Exp Toxicol Pathol. 2011;63(6):569\u201374.","journal-title":"Exp Toxicol Pathol"},{"key":"4886_CR118","doi-asserted-by":"crossref","unstructured":"Kawaratani H, et al. The effect of inflammatory cytokines in alcoholic liver disease. Media Inflammation. 2013;2013:495156.","DOI":"10.1155\/2013\/495156"},{"issue":"1","key":"4886_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4254\/wjh.v10.i1.1","volume":"10","author":"JA Del Campo","year":"2018","unstructured":"Del Campo JA, Gallego P, Grande L. Role of inflammatory response in liver diseases: Therapeutic strategies. World J Hepatol. 2018;10(1):1.","journal-title":"World J Hepatol"},{"issue":"10","key":"4886_CR120","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.3390\/ijms21103714","volume":"21","author":"Z-H Goh","year":"2020","unstructured":"Goh Z-H, Tee JK, Ho HK. An evaluation of the in vitro roles and mechanisms of Silibinin in reducing pyrazinamide-and isoniazid-induced hepatocellular damage. Int J Mol Sci. 2020;21(10):3714.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4886_CR121","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0168-8278(89)90083-4","volume":"9","author":"P Ferenci","year":"1989","unstructured":"Ferenci P, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989;9(1):105\u201313.","journal-title":"J Hepatol"},{"issue":"1","key":"4886_CR122","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/0168-8278(91)90912-U","volume":"12","author":"B Nalpas","year":"1991","unstructured":"Nalpas B, et al. Association between HCV and HBV infection in hepatocellular carcinoma and alcoholic liver disease. J Hepatol. 1991;12(1):70\u20134.","journal-title":"J Hepatol"},{"issue":"3","key":"4886_CR123","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/0168-8278(91)90079-Q","volume":"13","author":"S Brillanti","year":"1991","unstructured":"Brillanti S, et al. Serological and histological aspects of hepatitis C virus infection in alcoholic patients. J Hepatol. 1991;13(3):347\u201350.","journal-title":"J Hepatol"},{"issue":"5","key":"4886_CR124","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.2337\/dc06-2247","volume":"30","author":"G Targher","year":"2007","unstructured":"Targher G, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30(5):1212\u20138.","journal-title":"Diabetes Care"},{"key":"4886_CR125","doi-asserted-by":"publisher","first-page":"464931","DOI":"10.3389\/fphar.2019.00877","volume":"10","author":"M-F Xia","year":"2019","unstructured":"Xia M-F, Bian H. NAFLD and diabetes: two sides of the same coin? Rationale for gene-based personalized NAFLD treatment. Front Pharmacol. 2019;10:464931.","journal-title":"Front Pharmacol"},{"issue":"2","key":"4886_CR126","first-page":"101","volume":"4","author":"HB Bhatt","year":"2015","unstructured":"Bhatt HB, Smith RJ. Fatty liver disease in diabetes mellitus. Hepatobiliary Surg Nutr. 2015;4(2):101.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"12","key":"4886_CR127","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1080\/13880209.2016.1199042","volume":"54","author":"Y Guo","year":"2016","unstructured":"Guo Y, et al. Silymarin improved diet-induced liver damage and insulin resistance by decreasing inflammation in mice. Pharm Biol. 2016;54(12):2995\u20133000.","journal-title":"Pharm Biol"},{"issue":"2","key":"4886_CR128","first-page":"108","volume":"44","author":"N Kheiripour","year":"2019","unstructured":"Kheiripour N, et al. Hepatoprotective effects of silymarin on liver injury via irisin upregulation and oxidative stress reduction in rats with type 2 diabetes. Iran J Med Sci. 2019;44(2):108.","journal-title":"Iran J Med Sci"},{"key":"4886_CR129","first-page":"812","volume":"3","author":"AT Elgarf","year":"2015","unstructured":"Elgarf AT, Mahdy MM, Sabri NA. Effect of silymarin supplementation on glycemic control, lipid profile and insulin resistance in patients with type 2 diabetes mellitus. Int J Adv Res. 2015;3:812\u201321.","journal-title":"Int J Adv Res"},{"issue":"46","key":"4886_CR130","first-page":"170","volume":"12","author":"S Mohammadi","year":"2013","unstructured":"Mohammadi S, et al. Effects of silymarin on insulin resistance and blood lipid profile in first-degree relatives of type 2 diabetic patients. J Med Plants. 2013;12(46):170\u20136.","journal-title":"J Med Plants"},{"issue":"6","key":"4886_CR131","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1002\/hep.23587","volume":"51","author":"J Wagoner","year":"2010","unstructured":"Wagoner J, et al. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology. 2010;51(6):1912\u201321.","journal-title":"Hepatology"},{"issue":"5","key":"4886_CR132","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1053\/j.gastro.2007.02.038","volume":"132","author":"SJ Polyak","year":"2007","unstructured":"Polyak SJ, et al. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-\u03baB signaling, and HCV infection by standardized silymarin. Gastroenterology. 2007;132(5):1925\u201336.","journal-title":"Gastroenterology"},{"issue":"2","key":"4886_CR133","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1053\/j.gastro.2009.09.021","volume":"138","author":"C Morishima","year":"2010","unstructured":"Morishima C, et al. Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology. 2010;138(2):671\u2013681. e2.","journal-title":"Gastroenterology"},{"issue":"3","key":"4886_CR134","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1053\/j.gastro.2009.11.053","volume":"138","author":"A Ahmed-Belkacem","year":"2010","unstructured":"Ahmed-Belkacem A, et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology. 2010;138(3):1112\u201322.","journal-title":"Gastroenterology"},{"issue":"3","key":"4886_CR135","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0168-8278(03)00239-3","volume":"39","author":"J Sch\u00fcmann","year":"2003","unstructured":"Sch\u00fcmann J, et al. Silibinin protects mice from T cell-dependent liver injury\u2606. J Hepatol. 2003;39(3):333\u201340.","journal-title":"J Hepatol"},{"issue":"5","key":"4886_CR136","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1053\/j.gastro.2008.07.072","volume":"135","author":"P Ferenci","year":"2008","unstructured":"Ferenci P, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon\/ribavirin therapy. Gastroenterology. 2008;135(5):1561\u20137.","journal-title":"Gastroenterology"},{"issue":"8","key":"4886_CR137","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3851\/IMP1942","volume":"16","author":"K Rutter","year":"2011","unstructured":"Rutter K, et al. Intravenous silibinin as \u2018rescue treatment\u2019for on-treatment non-responders to pegylated interferon\/ribavirin combination therapy. Antivir Ther. 2011;16(8):1327\u201333.","journal-title":"Antivir Ther"},{"issue":"3","key":"4886_CR138","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jhep.2012.09.034","volume":"58","author":"Z Mari\u00f1o","year":"2013","unstructured":"Mari\u00f1o Z, et al. Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period. J Hepatol. 2013;58(3):415\u201320.","journal-title":"J Hepatol"},{"issue":"8","key":"4886_CR139","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1365-2893.2011.01572.x","volume":"19","author":"M Biermer","year":"2012","unstructured":"Biermer M, et al. High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy. J Viral Hepatitis. 2012;19(8):547\u201353.","journal-title":"J Viral Hepatitis"},{"issue":"7","key":"4886_CR140","doi-asserted-by":"publisher","first-page":"e0133028","DOI":"10.1371\/journal.pone.0133028","volume":"10","author":"DL Braun","year":"2015","unstructured":"Braun DL, et al. A lead-in with silibinin prior to triple-therapy translates into favorable treatment outcomes in difficult-to-treat HIV\/hepatitis C coinfected patients. PLoS One. 2015;10(7):e0133028.","journal-title":"PLoS One"},{"issue":"10","key":"4886_CR141","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/hiv.12166","volume":"15","author":"D Braun","year":"2014","unstructured":"Braun D, et al. Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV\/hepatitis C virus-coinfected patients. HIV Med. 2014;15(10):625\u201330.","journal-title":"HIV Med"},{"key":"4886_CR142","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1016\/S0168-8278(12)60191-3","volume":"56","author":"S Beinhardt","year":"2012","unstructured":"Beinhardt S, et al. 178 intravenous silibinin-therapy IN patients with chronic hepatitis C IN the transplant setting. J Hepatol. 2012;56:S77\u20138.","journal-title":"J Hepatol"},{"issue":"6","key":"4886_CR143","doi-asserted-by":"publisher","first-page":"411","DOI":"10.5812\/hepatmon.6135","volume":"12","author":"A Aghemo","year":"2012","unstructured":"Aghemo A, et al. Failure of intravenous silibinin monotherapy to prevent hepatitis C genotype 2A liver graft reinfection. Hepat Mon. 2012;12(6):411.","journal-title":"Hepat Mon"},{"issue":"1","key":"4886_CR144","first-page":"1","volume":"9","author":"D Eurich","year":"2011","unstructured":"Eurich D, et al. Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy. Exp Clin Transplant. 2011;9(1):1\u20136.","journal-title":"Exp Clin Transplant"},{"issue":"3","key":"4886_CR145","first-page":"4320","volume":"8","author":"J Gu","year":"2015","unstructured":"Gu J, et al. An open-label, randomized and multi-center clinical trial to evaluate the efficacy of Silibinin in preventing drug-induced liver injury. Int J Clin Exp Med. 2015;8(3):4320.","journal-title":"Int J Clin Exp Med"},{"key":"4886_CR146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12906-015-0861-7","volume":"15","author":"C Luangchosiri","year":"2015","unstructured":"Luangchosiri C, et al. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury. BMC Complement Altern Med. 2015;15:1\u20137.","journal-title":"BMC Complement Altern Med"},{"issue":"2\u20133","key":"4886_CR147","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0162-0134(01)00198-2","volume":"85","author":"M Borsari","year":"2001","unstructured":"Borsari M, et al. Silybin, a new iron-chelating agent. J Inorg Biochem. 2001;85(2\u20133):123\u20139.","journal-title":"J Inorg Biochem"},{"issue":"2","key":"4886_CR148","first-page":"2578","volume":"8","author":"S Cetinkunar","year":"2015","unstructured":"Cetinkunar S, et al. The effect of silymarin on hepatic regeneration after partial hepatectomy: is silymarin effective in hepatic regeneration? Int J Clin Exp Med. 2015;8(2):2578.","journal-title":"Int J Clin Exp Med"},{"issue":"51","key":"4886_CR149","first-page":"2723","volume":"130","author":"J Feher","year":"1989","unstructured":"Feher J, et al. Liver-protective action of silymarin therapy in chronic alcoholic liver diseases. Orv Hetil. 1989;130(51):2723\u20137.","journal-title":"Orv Hetil"},{"issue":"6","key":"4886_CR150","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/ptr.6361","volume":"33","author":"V Soleimani","year":"2019","unstructured":"Soleimani V, et al. Safety and toxicity of silymarin, the major constituent of milk thistle extract: an updated review. Phytother Res. 2019;33(6):1627\u201338.","journal-title":"Phytother Res"},{"issue":"3","key":"4886_CR151","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1089\/jmf.2006.089","volume":"10","author":"SA-R Hussain","year":"2007","unstructured":"Hussain SA-R. Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes. J Med Food. 2007;10(3):543\u20137.","journal-title":"J Med Food"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-025-04886-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-025-04886-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-025-04886-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T11:02:49Z","timestamp":1744455769000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-025-04886-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":151,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4886"],"URL":"https:\/\/doi.org\/10.1186\/s12906-025-04886-y","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,12]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"134"}}